A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome

European Neuropsychopharmacology

Volumn 26, Issue 9, 2016, Pages 1353-1365

  Zimbron, Jorge ^a,b   Khandaker, Golam M ^a,b   Toschi, Chiara ^c   Jones, Peter B ^a   Fernandez Egea, Emilio ^a,b,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b FULBOURN HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Clozapine; Meta analysis; Metabolic syndrome; Schizophrenia; Treatment

Indexed keywords

ANTIOBESITY AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

CHEMICALLY INDUCED; HUMAN; META ANALYSIS; METABOLIC SYNDROME X; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-OBESITY AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; METABOLIC SYNDROME; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84995674855     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.07.010     Document Type: Article

References (63)

1. Afshar, H., Roohafza, H., Mousavi, G., Golchin, S., Toghianifar, N., Sadeghi, M., Talaei, M., Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J. Psychopharmacol. (Oxf.) 23 (2009), 157–162, 10.1177/0269881108089816.
2. Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C., Weiden, P.J., Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999), 1686–1696.
3. Bai, Y.M., Lin, C.C., Chen, J.Y., Chen, T.T., Su, T.P., Chou, P., Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. J. Clin. Psychiatry 72 (2011), 751–756, 10.4088/JCP.09m05402yel.
4. Ball, M.P., Warren, K.R., Feldman, S., McMahon, R.P., Kelly, D.L., Buchanan, R.W., Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin. Schizophr. Relat. Psychoses 5 (2011), 17–25, 10.3371/CSRP.5.1.3.
5. Basile, V.S., Masellis, M., McIntyre, R.S., Meltzer, H.Y., Lieberman, J.A., Kennedy, J.L., Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J. Clin. Psychiatry 62:Suppl 23 (2001), 45–66.
6. Behdani, F., Hebrani, P., Rezaei Ardani, A., Rafee, E., Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch. Iran. Med. 14 (2011), 270–275 doi:0011144/AIM.009.
7. Bodén, R., Edman, G., Reutfors, J., Ostenson, C.G., Osby, U., A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr. Dis. Treat. 9 (2013), 371–377, 10.2147/NDT.S40554.
8. Borovicka, M.C., Fuller, M.A., Konicki, P.E., White, J.C., Steele, V.M., Jaskiw, G.E., Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J. Clin. Psychiatry 63 (2002), 345–348.
9. Brenner, H.D., Dencker, S.J., Goldstein, M.J., Hubbard, J.W., Keegan, D.L., Kruger, G., Kulhanek, F., Liberman, R.P., Malm, U., Midha, K.K., At issue: defining treatment refractoriness in schizophrenia. Schizophr. Bull. 16 (1990), 551–561, 10.1093/schbul/16.4.551.
10. Carrizo, E., Fernández, V., Connell, L., Sandia, I., Prieto, D., Mogollón, J., Valbuena, D., Fernández, I., de Baptista, E.A., Baptista, T., Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr. Res. 113 (2009), 19–26, 10.1016/j.schres.2009.05.007.
11. Chen, C.H., Huang, M.C., Kao, C.F., Lin, S.K., Kuo, P.H., Chiu, C.C., Lu, M.L., Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 74 (2013), e424–e430, 10.4088/JCP.12m08186.
12. Cochrane Informatics & Knowledge Management Department, 2015. RevMan.
13. De Hert, M., Detraux, J., van Winkel, R., Yu, W., Correll, C.U., Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 8 (2011), 114–126, 10.1038/nrendo.2011.156.
14. De Luca, V., Mueller, D.J., de Bartolomeis, A., Kennedy, J.L., Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int. J. Neuropsychopharmacol. 10 (2007), 697–704, 10.1017/S1461145707007547.
15. European Medicines Agency, 2010. Questions and answers on the suspension of medicines containing sibutramine.
16. Fan, X., Borba, C.P.C., Copeland, P., Hayden, D., Freudenreich, O., Goff, D.C., Henderson, D.C., Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr. Scand. 127 (2013), 217–226, 10.1111/acps.12009.
17. Faulkner, G., Cohn, T., Remington, G., Interventions to reduce weight gain in schizophrenia, in: Cochrane Database of Systematic Reviews. 2007, John Wiley & Sons, Ltd., London, United Kingdom.
18. Faulkner, G., Soundy, A.A., Lloyd, K., Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr. Scand. 108 (2003), 324–332.
19. Fiedorowicz, J.G., Miller, D.D., Bishop, J.R., Calarge, C.A., Ellingrod, V.L., Haynes, W.G., Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr. Psychiatry Rev. 8 (2012), 25–36, 10.2174/157340012798994867.
20. Fleischhacker, W.W., Heikkinen, M.E., Olié, J.P., Landsberg, W., Dewaele, P., McQuade, R.D., Loze, J.Y., Hennicken, D., Kerselaers, W., Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 13 (2010), 1115–1125, 10.1017/S1461145710000490.
21. Freudenreich, O., Henderson, D.C., Macklin, E.A., Evins, A.E., Fan, X., Cather, C., Walsh, J.P., Goff, D.C., Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J. Clin. Psychiatry 70 (2009), 1674–1680, 10.4088/JCP.08m04683.
22. Friedman, J.I., Carpenter, D., Lu, J., Fan, J., Tang, C.Y., White, L., Parrella, M., Bowler, S., Elbaz, Z., Flanagan, L., Harvey, P.D., A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J. Clin. Psychopharmacol. 28 (2008), 59–63, 10.1097/jcp.0b013e318161318f.
23. Gianfrancesco, F.D., Grogg, A.L., Mahmoud, R.A., Wang, R., Nasrallah, H.A., Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J. Clin. Psychiatry 63 (2002), 920–930.
24. Hebrani, P., Manteghi, A.A., Behdani, F., Hessami, E., Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. J. Res. Med. Sci. 20 (2015), 364–371.
25. Henderson, D.C., Copeland, P.M., Daley, T.B., Borba, C.P., Cather, C., Nguyen, D.D., Louie, P.M., Evins, A.E., Freudenreich, O., Hayden, D., Goff, D.C., A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am. J Psychiatry 162 (2005), 954–962, 10.1176/appi.ajp.162.5.954.
26. Henderson, D.C., Fan, X., Copeland, P.M., Borba, C.P., Daley, T.B., Nguyen, D.D., Zhang, H., Hayden, D., Freudenreich, O., Cather, C., Evins, A.E., Goff, D.C., A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr. Scand. 115 (2007), 101–105, 10.1111/j.1600-0447.2006.00855.x.
27. Henderson, D.C., Fan, X., Sharma, B., Copeland, P.M., Borba, C.P., Boxill, R., Freudenreich, O., Cather, C., Eden Evins, A., Goff, D.C., A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr. Scand. 119 (2009), 457–465, 10.1111/j.1600-0447.2008.01325.x.
28. Henderson, D.C., Freudenreich, O., Borba, C.P.C., Wang, X., Copeland, P.M., Macklin, E., Fan, X., Cather, C., Goff, D.C., Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr. Res. 130 (2011), 53–56, 10.1016/j.schres.2011.04.009.
29. Higgins, J.P.T., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560, 10.1136/bmj.327.7414.557.
30. Hong, C.J., Lin, C.H., Yu, Y.W.Y., Chang, S.C., Wang, S.Y., Tsai, S.J., Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr. Genet. 12 (2002), 169–171.
31. Joffe, G., Takala, P., Tchoukhine, E., Hakko, H., Raidma, M., Putkonen, H., Eronen, M., Räsänen, P., Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 69 (2008), 706–711.
32. Kernan, W.N., Viscoli, C.M., Brass, L.M., Broderick, J.P., Brott, T., Feldmann, E., Morgenstern, L.B., Wilterdink, J.L., Horwitz, R.I., Phenylpropanolamine and the risk of hemorrhagic stroke. New Engl. J. Med. 343 (2000), 1826–1832, 10.1056/NEJM200012213432501.
33. Ko, Y.H., Joe, S.H., Jung, I.K., Kim, S.H., Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin. Neuropharmacol. 28 (2005), 169–175.
34. Lett, T.A.P., Wallace, T.J.M., Chowdhury, N.I., Tiwari, A.K., Kennedy, J.L., Müller, D.J., Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry 17 (2012), 242–266, 10.1038/mp.2011.109.
35. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Stapf, M.P., Lässig, B., Salanti, G., Davis, J.M., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–962, 10.1016/S0140-6736(13)60733-3.
36. Lucas, K.H., Kaplan-Machlis, B., Orlistat-a novel weight loss therapy. Ann. Pharmacother. 35 (2001), 314–328.
37. Maayan, L., Vakhrusheva, J., Correll, C.U., Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35 (2010), 1520–1530, 10.1038/npp.2010.21.
38. Meltzer, H.Y., 1994. An Overview of the Mechanism of Action of Clozapine. Journal of Clinical Psychiatry 55, no. Suppl B, 47–52.
39. Müller, D.J., Muglia, P., Fortune, T., Kennedy, J.L., Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol. Res., Trends Pharmacogenomics 49 (2004), 309–329, 10.1016/j.phrs.2003.05.001.
40. Muscatello, M.R.A., Bruno, A., Pandolfo, G., Micò, U., Bellinghieri, P.M., Scimeca, G., Cacciola, M., Campolo, D., Settineri, S., Zoccali, R., Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J. Psychopharmacol. (Oxf.) 25 (2011), 667–674, 10.1177/0269881110372548.
41. NICE, 2014. CG178 Psychosis and schizophrenia in adults: NICE guideline [WWW Document]. NICE. URL 〈http://www.nice.org.uk/〉 (accessed 6.12.14).
42. Novartis, 2002. Clozaril. Summary of product characteristics for the FDA.
43. Padwal, R., Li, S.K., Lau, D.C.W., Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst. Rev., 2004, CD004094, 10.1002/14651858.CD004094.pub2.
44. Reynolds, G.P., Pharmacogenetic aspects of antipsychotic drug-induced weight gain - a critical review. Clin. Psychopharmacol. Neurosci. 10 (2012), 71–77, 10.9758/cpn.2012.10.2.71.
45. Reynolds, G.P., Kirk, S.L., Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol. Ther. 125 (2010), 169–179, 10.1016/j.pharmthera.2009.10.010.
46. Rietschel, M., Naber, D., Fimmers, R., Möller, H.J., Propping, P., Nöthen, M.M., Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 8 (1997), 1999–2003.
47. Saha, S., Chant, D., McGrath, J., A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 64 (2007), 1123–1131, 10.1001/archpsyc.64.10.1123.
48. Schulz, K.F., Altman, D.G., Moher, D., for the CONSORT Group. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med., 7, 2010, e1000251, 10.1371/journal.pmed.1000251.
49. Sicard, M.N., Zai, C.C., Tiwari, A.K., Souza, R.P., Meltzer, H.Y., Lieberman, J.A., Kennedy, J.L., Müller, D.J., Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 11 (2010), 1561–1571, 10.2217/pgs.10.123.
50. Spencer, T., Biederman, J., Wilens, T., Prince, J., Hatch, M., Jones, J., Harding, M., Faraone, S.V., Seidman, L., Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 155 (1998), 693–695.
51. Sudhakar, T., Rao, Gp, Prasuna, Pl, Vijay Sagar, Kj, Study of effects of modafinil add-on therapy on excessive day time drowsiness and weight gain in patients on atypical antipsychotics. Indian J. Psychol. Med., 30, 2008, 24, 10.4103/0253-7176.43131.
52. Tchoukhine, E., Takala, P., Hakko, H., Raidma, M., Putkonen, H., Rasanen, P., Terevnikov, V., Stenberg, J.H., Eronen, M., Joffe, G., Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J. Clin. Psychiatry 72 (2011), 326–330 doi:Article.
53. Theisen, F.M., Gebhardt, S., Haberhausen, M., Heinzel-Gutenbrunner, M., Wehmeier, P.M., Krieg, J.C., Kühnau, W., Schmidtke, J., Remschmidt, H., Hebebrand, J., Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr. Genet. 15 (2005), 285–289.
54. Thompson, A., Shaw, M., Harrison, G., Ho, D., Gunnell, D., Verne, J., Patterns of hospital admission for adult psychiatric illness in England: analysis of Hospital Episode Statistics data. Br. J. Psychiatry 185 (2004), 334–341, 10.1192/bjp.185.4.334.
55. Vehof, J., Risselada, A.J., Al Hadithy, A.F.Y., Burger, H., Snieder, H., Wilffert, B., Arends, J., Wunderink, L., Knegtering, H., Wiersma, D., Cohen, D., Mulder, H., Bruggeman, R., Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl. ) 216 (2011), 257–265, 10.1007/s00213-011-2211-x.
56. Wang, M., Tong, J., Zhu, G., Liang, G., Yan, H., Wang, X., Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr. Res. 138 (2012), 54–57, 10.1016/j.schres.2012.02.021.
57. Whitney, Z., Procyshyn, R.M., Fredrikson, D.H., Barr, A.M., Treatment of clozapine-associated weight gain: a systematic review. Eur. J. Clin. Pharmacol. 71 (2015), 389–401, 10.1007/s00228-015-1807-1.
58. Wiernsperger, N.F., Bailey, C.J., The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 58:Suppl 1 (1999), 31–39 discussion 75–82.
59. Wirshing, D.A., Wirshing, W.C., Kysar, L., Berisford, M.A., Goldstein, D., Pashdag, J., Mintz, J., Marder, S.R., Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry 60 (1999), 358–363.
60. Wu, M.K., Wang, C.K., Bai, Y.M., Huang, C.Y., Lee, S.D., Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr. Serv. 58 (2007), 544–550, 10.1176/appi.ps.58.4.544.
61. Yamada, J., Sugimoto, Y., Yoshikawa, T., Noma, T., Horisaka, K., The effects of peripheral serotonin2 receptor agonist on food intake of rats. Adv. Exp. Med. Biol. 398 (1996), 555–557.
62. Yevtushenko, O., Lafferty, C., Aziz, V., Tyson, A., Jamil, N., Reynolds, G.P., Pharmacogenetics of weight gain and obesity following clozapine treatment. Eur. Psychiatry, 15th AEP Congr. Abstr. book 15th AEP Congr., 22(Supplement 1), 2007, S318, 10.1016/j.eurpsy.2007.01.1058.
63. Yki-Järvinen, H., Thiazolidinediones. New Engl. J. Med. 351 (2004), 1106–1118, 10.1056/NEJMra041001.